Willmore L J
Department of Neurology, Saint Louis University School of Medicine, MO 63104, USA.
Neurology. 2000;55(11 Suppl 3):S17-24.
Advances in neurobiology, molecular biology, and pharmaceutical science have led to the development of a number of new antiepileptic drugs (AEDs). The investigational AEDs described in this review include ganaxolone, levetiracetam, losigamone, pregabalin, remacemide, rufinamide, stiripentol, and zonisamide. They have shown efficacy in a variety of seizure types and offer hope for improved therapeutic efficacy, beneficial pharmacokinetics, and a decrease in the incidence of drug interactions and adverse events. As the results of ongoing clinical trials of these drugs become available, these medications may be considered for rational drug therapy of epilepsy, either singly or in combination with currently available AEDs.
神经生物学、分子生物学和制药科学的进展已促成了多种新型抗癫痫药物（AEDs）的研发。本综述中描述的研究性抗癫痫药物包括加奈索酮、左乙拉西坦、洛西加酮、普瑞巴林、瑞玛西胺、卢非酰胺、司替戊醇和唑尼沙胺。它们在多种癫痫发作类型中均显示出疗效，并为提高治疗效果、获得有益的药代动力学特性以及降低药物相互作用和不良事件的发生率带来了希望。随着这些药物正在进行的临床试验结果的公布，这些药物可被考虑单独或与现有抗癫痫药物联合用于癫痫的合理药物治疗。
